Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -20.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 17.10 | 8.29 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.67 | 5.96 | 50.24 | 10.06 | 10.39 | 3.35 | 5.99 | 6.00 | 18.09 | 17.21 | 21.17 | 6.34 | 5.16 | 8.20 | 21.98 | 18.05 | 14.21 | 13.51 | 4.77 | 3.93 | 24.21 |
| — | +78.1% | +739.2% | +67.6% | -42.5% | -80.6% | -71.7% | -5.2% | +250.4% | +109.8% | -3.7% | -64.9% | -63.7% | -39.3% | +361.2% | +359.3% | -41.3% | +75.1% | -74.1% | -73.8% | +54.1% | |
| P/B Ratio | 2.90 | 2.43 | 1.76 | 1.79 | 1.40 | 0.94 | 1.22 | 2.49 | 1.79 | 2.08 | 2.26 | 1.95 | 1.83 | 2.20 | 2.44 | 2.14 | 2.15 | 2.20 | 2.14 | 3.30 | 3.08 |
| — | +157.9% | +43.7% | -28.3% | -21.8% | -54.7% | -45.8% | +27.9% | -2.2% | -5.7% | -7.4% | -9.0% | -14.9% | +0.2% | +14.2% | -35.0% | -30.3% | -31.7% | -50.1% | -24.8% | -21.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | 18.79 | — | — | — | — | — | 13.76 | 144.47 | 10.91 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -77.7% | — | |
| EV / EBITDA | — | — | — | — | — | — | — | 66.49 | — | — | — | — | — | — | — | — | — | — | 13.84 | 6.16 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 102.84 | 159.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | 14.98 | 6.24 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.6% | 100.0% | 43.2% | 90.9% | -158.9% | 93.9% | 91.8% | 100.0% | -227.2% | 82.2% | -255.5% | 93.7% | -9.8% | -31.9% | -245.7% | -138.1% | -95.1% | -56.0% | 44.1% | 66.9% | -157.1% |
| — | +6.5% | -53.0% | -9.1% | +30.1% | +14.3% | +135.9% | +6.8% | -2226.7% | +357.3% | -4.0% | +167.8% | +89.7% | +43.0% | -656.6% | -306.4% | +39.4% | -310.6% | +301.4% | +559.4% | -511.6% | |
| Operating Margin | -141.4% | -72.4% | -1724.1% | -189.9% | -226.3% | -76.1% | -131.9% | 5.8% | -310.2% | -367.4% | -341.7% | -56.4% | -30.9% | -57.1% | -320.3% | -197.1% | -140.5% | -92.8% | 31.0% | 59.5% | -209.8% |
| — | +4.9% | -1206.9% | -3385.9% | +27.0% | +79.3% | +61.4% | +110.3% | -904.4% | -543.4% | -6.7% | +71.4% | +78.0% | +38.5% | -1134.8% | -431.2% | +33.1% | -788.7% | +167.1% | +281.8% | -343.8% | |
| Net Margin | -73.2% | -42.4% | -2854.7% | -23.6% | -28.7% | -70.7% | -147.9% | -76.4% | -260.1% | -388.9% | -459.1% | -51.3% | -41.0% | -48.2% | -320.4% | -55.7% | -120.0% | -112.6% | 27.6% | 47.4% | -204.2% |
| — | +40.0% | -1829.8% | +69.2% | +89.0% | +81.8% | +67.8% | -48.9% | -534.1% | -706.5% | -43.3% | +7.9% | +65.8% | +57.2% | -1261.2% | -217.5% | +41.2% | -245.3% | +476.9% | +245.0% | -475.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.0% | -4.3% | -22.4% | -1.1% | -1.0% | -4.9% | -7.4% | -7.7% | -7.2% | -11.4% | -11.6% | -3.9% | -3.6% | -3.2% | -8.6% | -1.7% | -4.5% | -4.5% | 3.2% | 10.8% | -6.4% |
| — | +12.8% | -203.9% | +86.2% | +86.6% | +56.9% | +36.7% | -95.2% | -100.3% | -252.2% | -35.2% | -136.6% | +19.5% | +28.6% | -373.1% | -115.4% | +29.6% | -153.2% | +832.8% | +550.2% | -188.2% | |
| ROA | -10.1% | -3.0% | -16.0% | -0.8% | -0.7% | -3.5% | -5.2% | -5.5% | -5.1% | -7.7% | -7.9% | -3.0% | -3.1% | -2.8% | -7.4% | -1.4% | -3.9% | -4.0% | 2.8% | 9.5% | -5.8% |
| — | +14.0% | -206.6% | +86.2% | +86.5% | +54.9% | +33.9% | -84.2% | -64.0% | -175.8% | -7.1% | -109.4% | +19.7% | +30.2% | -364.8% | -115.1% | +32.7% | -152.8% | +880.8% | +569.0% | -196.8% | |
| ROIC | -16.3% | -4.6% | -8.1% | -5.1% | -4.9% | -3.8% | -4.2% | 0.4% | -5.9% | -6.5% | -4.9% | -2.8% | -2.0% | -2.8% | -6.5% | -4.4% | -4.0% | -2.9% | 3.0% | 11.1% | -5.4% |
| — | -22.1% | -91.2% | -1488.2% | +16.6% | +41.5% | +13.3% | +113.2% | -198.3% | -128.3% | +24.9% | +36.5% | +50.0% | +1.7% | -319.7% | -139.7% | +26.4% | -302.1% | +205.4% | +609.2% | -113.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.13 | 0.34 | 0.30 | 0.32 | 0.11 | 0.11 | 0.34 | 0.12 | 0.16 | 0.42 | 0.38 | 0.09 | 0.09 | 0.09 | 0.08 | 0.06 | 0.06 | 0.05 | 0.05 | 0.06 |
| — | +18.3% | +220.5% | -14.2% | +169.5% | -29.7% | -75.0% | -9.6% | +32.3% | +79.8% | +388.7% | +364.2% | +52.3% | +54.7% | +89.5% | +77.0% | +7.8% | +621.4% | +139.8% | +128.0% | +229.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | 32.94 | — | — | — | — | — | — | — | — | — | — | 1.22 | 0.36 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.25 | 6.39 | 6.57 | 6.25 | 5.99 | 5.34 | 5.89 | 6.61 | 6.23 | 6.92 | 8.09 | 8.60 | 10.77 | 13.30 | 9.68 | 10.58 | 7.42 | 7.81 | 8.30 | 6.00 | 7.44 |
| — | +19.7% | +11.5% | -5.3% | -3.8% | -22.9% | -27.1% | -23.2% | -42.1% | -47.9% | -16.5% | -18.7% | +45.1% | +70.3% | +16.6% | +76.3% | -0.2% | -25.4% | +40.3% | +13.9% | -8.2% | |
| Quick Ratio | 6.25 | 6.39 | 6.57 | 6.25 | 5.99 | 5.34 | 5.89 | 6.61 | 6.23 | 6.92 | 8.09 | 8.60 | 10.77 | 13.30 | 9.68 | 10.58 | 7.42 | 7.81 | 8.30 | 6.00 | 7.44 |
| — | +19.7% | +11.5% | -5.3% | -3.8% | -22.9% | -27.1% | -23.2% | -42.1% | -47.9% | -16.5% | -18.7% | +45.1% | +70.3% | +16.6% | +76.3% | -0.2% | -25.4% | +40.3% | +13.9% | -8.2% | |
| Interest Coverage | -1.80 | -1.98 | -26.37 | 0.42 | 0.21 | -2.77 | -4.57 | -0.55 | -48.32 | -78.73 | -6.66 | -1.05 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XNCR stock.
Xencor, Inc.'s current P/E is -20.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xencor, Inc.'s current operating margin is -141.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xencor, Inc.'s business trajectory between earnings reports.